Behrns KE, Smith CD, Kelly KA, Sarr MG Reoperative bariatric surgery. Lessons learned to improve patient selection and results. Ann Surg. 1993 Nov;218(5):646-53.
Bradley JE, Brown RO, Luther RW Multiple nutritional deficiencies and metabolic complications 20 years after jejunoileal bypass surgery. JPEN J Parenter Enteral Nutr. 1987 Sep-Oct;11(5):494-8.
Higa KD, Boone KB, Ho T, Davies OG Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients. Arch Surg. 2000 Sep;135(9):1029-33; discussion 1033-4.
Meguid MM, Glade MJ, Middleton FA Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008 Sep;24(9):832-42. doi: 10.1016/j.nut.2008.06.027. Review.
Nguyen NT Reoperations and revisions in bariatric surgery. Surg Endosc. 2007 Nov;21(11):1907-8. Epub 2007 Sep 8.
O'Brien P, Brown W, Dixon J Revisional surgery for morbid obesity--conversion to the Lap-Band system. Obes Surg. 2000 Dec;10(6):557-63.
Raftopoulos I, Courcoulas AP Revision of jejunoileal bypass to Roux-en-Y gastric bypass: technical considerations and outcomes from 2 cases. Surg Obes Relat Dis. 2008 Mar-Apr;4(2):198-201. Epub 2007 Dec 11.
Tapper D, Hunt TK, Allen RC, Campbell J Conversion of jejunoileal bypass to gastric bypass to maintain weight loss. Surg Gynecol Obstet. 1978 Sep;147(3):353-7.
Wands JR, LaMont JT, Mann E, Isselbacher KJ Arthritis associated with intestinal-bypass procedure for morbid obesity. Complement activation and characterization of circulating cryoproteins. N Engl J Med. 1976 Jan 15;294(3):121-4.
One-stage Laparoscopic Revision of Failed and/or Complicated Jejunoileal Bypass to Roux-en-Y Gastric Bypass
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.